The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

WCMM Fellows Receive VR Grant

Martin Magnusson, clinical WCMM fellow and adjunct professor in cardiovascular research
Martin Magnusson, clinical WCMM fellow and adjunct professor in cardiovascular research

Martin Magnusson received a 4.8 million VR project grant 2023-2026 for the project "Incretin system´s impact on cardiovascular disease and cancer" together with Joao Duarte and Anja Meissner. The aim of this study is to assess the long-term effects of incretin hormones GIP and GLP-1 on the cardiovascular system. These hormones initiate insulin secretion, which reduces blood sugar levels after a meal to normal levels. However, in type 2 diabetes patients this process is impaired and insulin production hampered. To counteract this, GIP and GLP-1 are given to diabetes patients by infusion.

In a new study led by Amra Jujic (postdoc in Martin Magnussons research group), which was published in Diabetologia in January 2020 (Jujić, A. et al. Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.Diabetologia. 2020), it was shown that high levels of GIP are linked to a greater risk of future cardiovascular disease (CVD) and mortality as well as subclinical atherosclerosis. This was the first study in which measurements were taken across a large population to investigate the link between the levels of GIP and GLP-1 in the blood and measurements of early arteriosclerosis. But the number of diabetic participants was low in this study, so it is not known how GIP levels affect the arteriosclerosis process in a purely diabetic population.

Now Martin Magnussons and co-applicants proposed to validate how high levels of GIP associates with adverse outcomes also in exclusively diabetic subjects from the Swedish All New Diabetics in Scania cohort.Furthermore, the mechanisms behind the harmful actions mediated by GIP will be explored in two separate heart failure cohorts. In experimental studies, long-term cardiovascular effects of incretin infusion and GIP inhibition using a GIP-receptor antagonist will be examined using mouse models. Lastly in exploratory studies, Martins team will invastigate GIP and GLP-1 associations with cancer incidence and statin usage.

Read more about Martin Magnussons study at the following press release “Incretin hormone levels linked to arteriosclerosis”.